Teladoc (TDOC) Falls More Steeply Than Broader Market: What Investors Need to Know

Core Insights - Teladoc's stock closed at $5.47, down 1.8%, underperforming the S&P 500 which lost 0.08% [1] - Over the past month, Teladoc's shares gained 14.85%, outperforming the Medical sector's loss of 2.21% and the S&P 500's loss of 2.16% [1] Earnings Performance - The upcoming EPS for Teladoc is projected at -$0.3, reflecting a 57.89% decline compared to the same quarter last year [2] - Revenue is estimated at $614.34 million, indicating a 2.39% decrease from the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are expected to be -$0.89 per share, with revenue projected at $2.52 billion, showing changes of +21.93% and -0.45% respectively from the previous year [3] - Recent analyst estimate revisions are crucial as they reflect near-term business trends, with positive revisions indicating a favorable business outlook [3] Zacks Rank and Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have an average annual return of +25% since 1988 [5] - Teladoc currently holds a Zacks Rank of 3 (Hold), with a recent 5.31% increase in the consensus EPS estimate over the last 30 days [5] Industry Insights - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]